Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Purespring launches for kidney gene therapies

by Michael McCoy
November 28, 2020 | A version of this story appeared in Volume 98, Issue 46

 

Purespring Therapeutics has launched with about $60 million in series A financing from the health-care investment firm Syncona to develop gene therapies focused on the kidney. Purespring is based on technology from Moin Saleem, a professor of pediatric renal medicine at the University of Bristol. It’s Syncona’s sixth gene therapy company since 2012. Biogen acquired one of them, Nightstar, last year for $877 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.